 |
Scientific Programme
8.00 - 8.30 Registration
8.30 - 9.00 Opening Ceremony
Session I. Novel insights in bone cell regulation and function
9.00 - 9.20 |
|
Anatagonist of the WNT pathway: Sclerostin |
|
T. BELLIDO (INDIANAPOLIS, USA) |
|
9.20 - 9.40 |
|
Regulation of osteoblastic cell differentation and function by CTGF |
|
E. CANALIS (HARTFORD, USA) |
|
|
9.40 - 9.50 |
|
Discussion |
|
|
|
9.50 - 10.10 |
|
"Hot Topics" Session |
|
|
Plenary Lecture
10.10 - 10.40 |
|
Clinical applications of RANK-L neutralization |
|
L. HOFBAUER (DRESDEN, GERMANY) |
|
10.40 - 11.00 |
|
Coffee break |
|
|
Session II.
Hypothalamic-pituitary thyroid axis and bone
11.00 - 11.20 |
|
Thyroid hormone and bone |
|
G. R. WILLIAMS (LONDON, UK) |
|
11.20 - 11.40 |
|
TSH and bone: basic aspects |
|
M. ZAIDI (NEW YORK, USA) |
|
|
11.40 - 12.00 |
|
TSH and bone: clinical aspects
|
|
G. MAZZIOTTI (MANTOVA, ITALY) |
|
12.00 - 12.15 |
|
Discussion |
|
|
Session III.
Steroid receptor modulators: novel insights
12.15 - 12.35 |
|
New SERMS: can one molecule achieve the goal of the "ideal" SERM? |
|
B. S. KOMM (COLLEGEVILLE, USA) |
|
12.35 - 13.05 |
|
Selective Steroid receptor modulators: maintaining bone integrity with overall clinical benefit |
|
A. NEGRO VILAR
(WASHINGTON D.C., USA) |
|
|
13.05 - 13.15 |
|
|
|
|
|
13.15 - 14.00 |
|
Lunch and Guided Poster session |
|
14.00 - 14.50 |
|
Parallel Oral Communications Session I & II |
Session IV.
Anabolic agents/1
14.50 - 15.10 |
|
Mechanisms of anabolic PTH action |
|
R.L. JILKA (LITTLE ROCK, USA) |
|
15.10 - 15.30 |
|
Clinical Aspects of Anabolic Therapy for Osteoporosis with Teriparatide and PTH 1-84 |
|
J. P. BILEZIKIAN (NEW YORK, USA) |
|
|
15.30 - 15.40 |
|
|
|
|
Session V.
Anabolic agents/2
15.40 - 16.00 |
|
Strontium Ranelate |
|
S. ORTOLANI (MILANO, ITALY) |
|
16.00 - 16.20 |
|
GH/IGF-1 and bone: lessons from acromegaly and GHD |
|
L. DE MARINIS (ROMA, ITALY) |
|
|
16.20 - 16.30 |
|
|
|
|
Session VI.
Bisphosphonate action: what matters?
16.30 - 16.50 |
|
I. V. Bisphosphonates |
|
S. ADAMI (VERONA, ITALY) |
|
16.50 - 17.10 |
|
How long to treat and long term reduction of fracture risk |
|
D. BARAN (WORCESTER, USA) |
|
|
17.10 - 17.25 |
|
Safety and tolerability of bisphosphonates for the treatment of osteoporosis |
|
F. BERTOLDO (VERONA, ITALY) |
|
17.25 - 17.40 |
|
ONJ |
|
G. CAMPISI (PALERMO, ITALY) |
|
17.45 - 17.55 |
|
Discussion |
|
|
17.55 - 18.00 Conclusions
|
|
